What's the best way to calculate the return-on-investment (ROI) of your disease management (DM) programs? Is there a standardized methodology for evaluating programs? And what ROI are employers currently seeing from their DM programs?
Quantifying Disease Management Return-on-Investment: Trends, Metrics, Evaluations, Transparency and Reality contains insider information from three leading experts in DM analytics. They review key principles in calculating ROI, how to establish metrics for evaluating DM programs, and common mistakes in measuring ROI. They also share some relevant case studies for comparison.
Quantifying Disease Management Return-on-Investment: Trends, Metrics, Evaluations, Transparency and Reality contains commentary from: Ron Z. Goetzel, Ph.D., Director, Cornell University Institute for Health and Productivity Studies; and VP of Consulting and Applied Research, Thomson Healthcare, Thomas Wilson, Ph.D., DrPH, Epidemiologist, Trajectory® Healthcare, LLC, Matthew McGinnis, Senior Director of the Center for Health Research, Healthways Inc.
Get information and insight from these experts on:
- Key considerations when evaluating an ROI methodology
- What are the strengths and weaknesses of current ROI methodologies, including:
- Propensity Score Methods
- Retrospective ROI
- Pre-intervention/post-intervention studies
- Annual qualification
- Prospective ID
- Longitudinal or time series analysis
- Participant/non-participant
- The relationship between 10 modifiable risk factors and healthcare costs
- Why does so much variability exist in current ROI methodologies?
- Results of published DM case studies on ROI from
- Dow Chemical
- Citibank
- Procter & Gamble
- Critique of peer-reviewed literature studies on DM ROI
- Trajectory Healthcare’s five critical principles in ROI measurement
- American Healthways’s 8 steps in evaluating historical ROI versus Month After Identification methodologies
Table of Contents
- ROI versus Net Present Value
- Projecting ROI Prospectively – Dow Chemical Company
- Steps of Evaluation
- Retrospective ROI
- What is The Unit of Analysis?
- Propensity Score Methods
- Case Studies
- Literature Reviews
- H.O.P.E.™
- The Trajectory® of a High Risk CHF Population
- The Reality
- Why Does the Evidence Appear to Be Insufficient?
- Standardized Evaluation Framework to Assess Multiple Methods
- The State of the (Published) Art
- The State of the (un-published) Art
- Transparency and Replicability
- OUTPUT: Quality Evaluation Process
- Annual Qualification Prospective ID Annual Qualification vs. Prospective ID: Clinical Compliance
- Trends in Disease Management Analysis
- Regression to the Mean
- A Case Study in ROI Methodologies
- Ask the Experts
- Glossary
- More Information
- About The Managed Care Information Center
- About The Contributors
|